Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity

Keyphrases

• Kinase Inhibitor 100%
• Caenorhabditis Elegans 100%
• Neurodegeneration 100%
• Leucine-rich Repeat Kinase 2 (LRRK2) 100%
• R1441C 21%
• G2019S 15%
• Kinase Activity 10%
• Kinase Domain 10%
• Parkinson's Disease 5%
• In Vitro Activity 5%
• Phosphorylation 5%
• Therapeutic Potential 5%
• Mutant Protein 5%
• Therapeutic Strategies 5%
• Transfected Cells 5%
• Neuroprotective Effect 5%
• Kinase Inhibition 5%
• Neurotoxicity 5%
• Neurodegenerative 5%
• Inhibitor Resistant 5%
• G2019S mutation 5%
• Caenorhabditis Elegans Model 5%
• Transgenic Worms 5%
• Transgenic C. Elegans 5%
• Small Molecule Targeting 5%
• Late-onset Parkinson's Disease 5%
• Behavioral Deficits 5%
• Dopaminergic Deficit 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphotransferase Inhibitor 100%
• Nerve Degeneration 100%
• Leucine Rich Repeat Kinase 2 100%
• Caenorhabditis Elegans 100%
• Phosphotransferase 26%
• Parkinson's Disease 10%
• Dopamine Receptor Stimulating Agent 10%
• Neuroprotective Agent 5%
• Mutant Protein 5%
• Neurotoxicity 5%

Neuroscience

• Kinase 100%
• Neurodegeneration 100%
• Leucine Rich Repeat Kinase 2 100%
• Caenorhabditis Elegans 100%
• In Vitro 10%
• Parkinson's Disease 10%
• Dopaminergic 10%
• In Vivo 5%
• Neuroprotective Agent 5%
• Neurotoxicity 5%
• Mutant Protein 5%